| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Product Strategy Officer | Sr. VP, New Prod. Strat. & Dev | Sr. VP, New Product Dev.
1 company
Tara Lynn Kieffer is Chief Product Strategy Officer at ENTA. Tara Lynn Kieffer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $352K at current prices.
Our model assigns Tara Lynn Kieffer a middling insider score of 54/100, based on 4 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of -10.3%.
The ENTA filings lean toward selling, a net 13,780 shares.
Tara Lynn Kieffer has 19 Form 4 filings on record from December 2020 to February 2026, all as Chief Product Strategy Officer at Enanta Pharmaceuticals (ENTA), 2020–2026.
The 29 reported transactions were 10 stock awards, 9 tax withholdings, 6 option or other derivative awards and 4 open-market sales.
Counted by filing, the open-market trades come to no purchases and 4 sales worth about $158K.
The largest open-market sale was 7,266 shares of ENTA at an average $12.33 on June 17, 2024, about $90K. Twelve months later ENTA was down 42%.
2 of the 4 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | ENTA Enanta Pharmaceuticals Inc | Chief Product Strategy Officer | Sell | 2,106 | $14.23 | $29,968.38 | -6.4% | -5.8% | - | |
| Dec 6, 2024 | ENTA Enanta Pharmaceuticals Inc | Chief Product Strategy Officer | Sell10b5-1 | 2,283 | $8.06 | $18,400.98 | -7.2% | -10.3% | +82.5% | |
| Jun 17, 2024 | ENTA Enanta Pharmaceuticals Inc | Chief Product Strategy Officer | Sell10b5-1 | 7,266 | $12.33 | $89,589.78 | -18.3% | -2.2% | -41.6% | |
| Dec 5, 2023 | ENTA Enanta Pharmaceuticals Inc | Sr. VP, New Prod. Strat. & Dev | Sell | 2,125 | $9.63 | $20,463.75 | -5.4% | +65.3% | -9.9% |